Last Updated: November 16, 2026

Details for Patent: 9,439,921

« Back to Dashboard


Summary for Patent: 9,439,921
Title:Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Abstract:The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Inventor(s):Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
Assignee: Chiesi Farmaceutici SpA
Application Number:US15/049,727
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,439,921
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;
Patent landscape, scope, and claims:

US Patent 9,439,921: Cangrelor Formulation Claims, Patent Scope, Expiration, and Generic Risk

US Patent 9,439,921 protects a stability-controlled formulation of high-purity cangrelor, including formulations containing mannitol and/or sorbitol, low moisture, controlled pH, specified impurity limits, and storage in a sealed vessel under dry inert gas. The patent is formulation-specific rather than a broad patent on cangrelor, its chemical structure, or all uses of the drug.

The principal commercial product is Kengreal, an intravenous cangrelor product approved by the FDA in 2015 for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention who have not received a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.[1]

What patent is US 9,439,921?

US 9,439,921 is directed to stable pharmaceutical formulations of cangrelor. The patent claims were issued in 2016 and cover both the formulation itself and a sealed-container configuration designed to control moisture and degradation during storage.[2]

Field Patent information
US patent 9,439,921
Patent type Utility patent
Technology Stable cangrelor pharmaceutical formulations
Active ingredient Cangrelor or a salt thereof
Principal dosage form Solid pharmaceutical formulation for reconstitution
Key excipients Polyols, specifically mannitol and sorbitol
Key stability controls Moisture, pH, hydrolysis degradants, oxidation degradants
Container claims Sealed vessel under nitrogen or argon
Commercial relevance Kengreal intravenous cangrelor
Patent holder history The Medicines Company and related entities
FDA product Kengreal, NDA 204958

The claims use both “comprising” and “consisting of” formulations. That distinction materially affects infringement analysis.

What does US Patent 9,439,921 claim?

The 26 claims divide into two substantially parallel groups.

Claims 1-13 cover a formulation and a sealed vessel containing that formulation. Claims 14-26 repeat the same architecture with a narrower formulation defined as consisting of cangrelor, or a cangrelor salt, and mannitol and/or sorbitol.

Claim group 1: formulation and container

Independent claim 1 requires all of the following:

  1. High-purity cangrelor or a cangrelor salt as the active ingredient.
  2. One or more pharmaceutically acceptable excipients.
  3. Less than approximately 2.0% moisture by weight.
  4. A pH between approximately 7.0 and 9.5.
  5. A combined level of selected cangrelor hydrolysis and oxidation degradants of no more than approximately 1.5% by weight of cangrelor.
  6. At least one of impurities A through E as the selected degradants.

Claim 14 is narrower in formulation composition. It requires the formulation to consist of cangrelor or a cangrelor salt and mannitol and/or sorbitol. The use of “consisting of” limits the formulation to the listed components and any ingredients that do not materially alter the basic character of the formulation.

Claims 8 and 21 cover a sealed vessel containing the formulation under a chemically inert dry gas. Claims 9 and 22 narrow the gas to nitrogen or argon.

Claim architecture

Claim set Subject matter Main limitation
1 Pharmaceutical formulation Moisture, pH, impurity and excipient limitations
2 Formulation Combined degradants no more than about 1.3%
3 Formulation Individual impurity limits A-E
4 Formulation Impurities A and D each below about 0.5%
5 Formulation Polyol excipient
6 Formulation Mannitol and sorbitol
7 Formulation 16-21% cangrelor and 84-79% excipient
8 Sealed vessel Inert dry gas
9 Sealed vessel Nitrogen or argon
10 Sealed vessel Moisture below 5% for at least six months
11-13 Sealed vessel Twelve-month pH, moisture and impurity performance
14-26 Parallel formulation and vessel claims Narrower “consisting of” composition

What technical subject matter does the patent protect?

The patent protects a quality and stability profile rather than a new cangrelor molecule. The technical focus is the control of degradation in a moisture-sensitive formulation.

Moisture control

The formulation claims require less than about 2.0% moisture by weight. The container claims use a less stringent post-storage limit, generally less than 5.0% moisture after six or 12 months.

This creates two distinct infringement questions:

  • Whether the product falls below the initial formulation moisture threshold.
  • Whether the packaged product maintains the claimed moisture threshold over the specified storage period.

A formulation outside the initial moisture limit may avoid claims 1-7 and 14-20 even if it later satisfies the six- or 12-month storage limitations.

pH control

The claimed pH range is approximately 7.0 to 9.5. Claims 11-13 and 24-26 specify pH for a 1% solution by weight after 12 months.

The pH limitation is potentially significant because it is tied to a test condition. A competing product cannot be evaluated solely on the pH of the dry powder. The relevant evidence would include the preparation of the 1% solution, the measurement method, the timing of measurement, and whether the claimed pH range is met after storage.

Impurity control

The claims identify five selected degradants:

  • Impurity A
  • Impurity B
  • Impurity C
  • Impurity D
  • Impurity E

Claim 1 uses a combined maximum of approximately 1.5%. Claim 2 narrows that threshold to approximately 1.3%. Claim 3 sets separate limits:

Impurity Claimed individual limit
A Less than about 0.5%
B Less than about 0.2%
C Less than about 0.3%
D Less than about 0.2%
E Less than about 0.5%

Claims 11-13 use different post-storage thresholds. Claim 11 limits impurities A through D to no more than 1% each and impurity E to no more than 0.5%. Claims 12 and 13 use aggregate limits of 5% and 2%, respectively.

The claim language creates an analytical burden. A party evaluating infringement would need a validated assay capable of identifying and quantifying each named impurity, not merely total unspecified degradation products.

How broad are the independent claims?

Claim 1 is broad in formulation composition but narrow in quality attributes. It uses “comprising,” which generally permits additional excipients, buffers, stabilizers, or processing aids unless another limitation excludes them.

The claim does not require:

  • A particular vial size.
  • A particular reconstitution volume.
  • A particular intravenous dose.
  • A particular manufacturing process.
  • A particular cangrelor salt, provided the formulation falls within the claim.
  • A particular clinical indication.
  • A particular label or method of administration.

The claim does require the combined technical profile of moisture, pH, cangrelor purity, and selected degradants.

Claim 14 is narrower because it uses “consisting of” and identifies mannitol and/or sorbitol as the excipient system. It is more difficult to practice without falling within the claim if a competing product uses the same restricted composition, but it is easier to design around by using a different excipient system, subject to the broader claims 1-13.

What formulations are protected by the patent?

The most commercially relevant formulation is a cangrelor powder containing mannitol and/or sorbitol, with approximately 16-21% cangrelor and 84-79% excipient by weight.

Key formulation coverage

Formulation characteristic Coverage
Cangrelor active ingredient Required
High-purity cangrelor Required
Moisture below about 2% Required for core formulation claims
pH about 7.0-9.5 Required
Combined selected degradants below about 1.5% Required
Combined selected degradants below about 1.3% Narrower dependent claim
Polyol excipient Narrower claim
Mannitol and sorbitol Narrower claim
Cangrelor concentration of about 16-21% Narrower dependent claim
Nitrogen or argon headspace Container claims
Six- or 12-month stability profile Container claims

A competing formulation using a different excipient may still infringe claim 1 if it satisfies the broad “one or more pharmaceutically acceptable excipients” language. Conversely, use of a different excipient may avoid claim 14, but it would not automatically avoid the broader claim family.

When does US Patent 9,439,921 expire?

The patent term must be calculated from the relevant nonprovisional filing date, adjusted for any patent-term adjustment and subject to any terminal disclaimer. Public patent records identify the patent as a post-1995 US patent governed by the 20-year term framework under 35 U.S.C. § 154.[3]

The grant date, August 16, 2016, is not the expiration date. The practical expiration date is determined from the earliest effective nonprovisional priority date, not from the grant date. The patent record and USPTO Patent Center control the final expiration calculation, including any patent-term adjustment.[2]

For commercial diligence, the relevant conclusion is that US 9,439,921 is a formulation patent with a term extending well beyond Kengreal’s three-year new-drug exclusivity period. FDA approval exclusivity for Kengreal began in 2015 and expired in 2018, while the patent term operates independently.[1][4]

What is the Orange Book status of US 9,439,921?

Kengreal is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 204958.[5]

Orange Book listing is important because it can support a statutory patent certification process for an abbreviated new drug application. A generic applicant may be required to certify against listed patents under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The commercial impact depends on whether US 9,439,921 is listed for the relevant Kengreal presentation and whether the FDA accepts a generic applicant’s certification. A patent listed in the Orange Book does not establish validity or infringement. It gives the NDA holder a regulatory mechanism to receive notice of a Paragraph IV certification and potentially initiate litigation.

What Paragraph IV challenges could target this patent?

A generic applicant seeking approval before expiration could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.[4]

The most likely challenge theories would focus on claim construction, obviousness, written description, enablement, indefiniteness, and noninfringement.

Potential noninfringement strategies

A competing applicant could attempt to avoid the claims by:

  • Using a formulation with moisture at or above the claimed threshold.
  • Selecting excipients outside the mannitol and sorbitol limitations.
  • Using a different cangrelor concentration.
  • Demonstrating that the pH of the relevant 1% solution is outside the claimed range.
  • Controlling degradation through a formulation that does not meet the named impurity profile.
  • Using packaging or headspace conditions that do not satisfy the inert-gas claims.
  • Showing that the product does not maintain the required post-storage characteristics.

Because claim 1 is a “comprising” claim, adding another excipient alone may not avoid infringement. A design-around based on excipients would be stronger against claim 14 than against claim 1.

Potential validity arguments

A Paragraph IV challenger could examine:

  • Earlier cangrelor formulations containing polyols.
  • Prior-art teachings on low-moisture injectable powders.
  • Prior-art stability data for cangrelor.
  • Whether the claimed impurity thresholds represent an unexpected result.
  • Whether the specification supports the full pH, moisture and impurity ranges.
  • Whether terms such as “high purity,” “about,” and the impurity designations provide sufficient certainty.

The strongest validity issue would likely be whether the claimed combination of excipient composition, moisture, pH and impurity limits would have been obvious from prior cangrelor formulation work. The patent holder’s response would likely rely on the interaction among those parameters and the claimed storage stability.

Does the patent cover cangrelor biosimilars?

No. Cangrelor is a chemically synthesized small-molecule drug, not a biologic. A competing cangrelor product would generally proceed through the generic drug pathway under section 505(j), not the biosimilar pathway under section 351(k).[4][6]

The relevant risks are therefore:

  • Abbreviated new drug applications.
  • Paragraph IV certifications.
  • Formulation and stability design-arounds.
  • Pharmaceutical equivalence and bioequivalence.
  • Patent litigation under the Hatch-Waxman framework.

The Purple Book and biosimilar exclusivity concepts are not the primary regulatory framework for cangrelor.

Which companies own or commercialize cangrelor?

The Medicines Company developed and commercialized Kengreal after obtaining rights to the cangrelor program. Chiesi has commercial rights for Kengreal in relevant markets under arrangements involving The Medicines Company.[7]

Company Role
The Medicines Company Developer and historical NDA sponsor or rights holder
Chiesi Commercialization partner for Kengreal in relevant territories
Generic applicants Potential future challengers under section 505(j)
Contract manufacturers Potentially relevant to supply and manufacturing freedom to operate

Patent ownership and product commercialization are separate issues. A company commercializing Kengreal may not own every patent in the broader cangrelor landscape, and a patent assignment does not itself establish Orange Book listing or infringement.

What patent litigation affects US 9,439,921?

The key litigation risk is a future or existing Hatch-Waxman action following a Paragraph IV certification. A filing would typically trigger the statutory 45-day period for the NDA holder to bring an infringement action. A timely action can impose a 30-month stay on FDA approval, subject to statutory exceptions and court developments.[4]

The supplied claim set alone does not establish that a Paragraph IV certification has been filed or that a final validity or infringement decision exists. Patent litigation status must be distinguished from patent status:

  • A patent can remain in force without litigation.
  • An Orange Book listing does not prove validity.
  • A settlement can preserve market exclusivity without a merits judgment.
  • A court judgment may affect only particular claims or parties.

No settlement terms should be inferred solely from the existence of the patent or from Kengreal’s FDA listing.

How strong is the patent estate for Kengreal?

US 9,439,921 appears strategically important because it targets the commercial dosage-form attributes that a generic applicant must reproduce or sufficiently match for approval. Its strength is concentrated in formulation execution rather than molecule ownership.

Strengths

  • Multiple independent claim groups.
  • Coverage of both broad excipient formulations and narrower mannitol/sorbitol formulations.
  • Separate claims directed to packaging and inert gas.
  • Quantitative limits that can be tested analytically.
  • Post-storage stability claims extending beyond initial release testing.
  • Potential Orange Book relevance for an approved product.

Weaknesses

  • The claims depend on potentially contestable relative terms such as “about” and “high purity.”
  • Impurity designations A-E require clear analytical identification.
  • The formulation claims may be vulnerable to prior art disclosing cangrelor with polyols or comparable stability controls.
  • A competitor may design around the narrower mannitol/sorbitol and container claims.
  • The patent does not block every cangrelor formulation or every method of using cangrelor.

The estate is best characterized as a targeted formulation barrier. It is not a complete composition-of-matter barrier to cangrelor entry.

How does US 9,439,921 compare with method-of-use and manufacturing patents?

Patent category Protection Relevance to generic entry
Composition of matter Cangrelor molecule Potentially broad but generally earlier-expiring
Formulation Moisture, pH, impurities, excipients Central subject of US 9,439,921
Container and packaging Inert dry gas and stability Adds product and packaging constraints
Method of use PCI, platelet inhibition and dosing May support label-based infringement theories
Manufacturing Synthesis, purification and processing Can create supplier and API barriers
Regulatory exclusivity FDA approval exclusivity Separate from patent term

US 9,439,921 does not claim the PCI indication, platelet inhibition generally, or the cangrelor molecule as such. Its commercial value depends on whether a competing applicant must use a formulation with the claimed stability profile.

What generic launch scenarios exist?

Scenario 1: Full formulation match

A generic applicant copies the core cangrelor-mannitol/sorbitol formulation and meets the claimed moisture, pH and impurity parameters. This creates the highest infringement risk and likely invites a Paragraph IV dispute if the patent remains listed and unexpired.

Scenario 2: Excipient design-around

The applicant uses a different excipient system. This may avoid claim 14 and its dependents, but claim 1 remains relevant because it covers formulations with one or more pharmaceutically acceptable excipients.

Scenario 3: Stability-profile design-around

The applicant uses a different process or formulation that produces a pH or impurity profile outside the claimed ranges. This may avoid literal infringement, but it must still satisfy FDA quality and stability requirements.

Scenario 4: Post-expiration launch

The applicant waits until patent expiration or obtains a license. This removes the patent-based launch barrier but does not eliminate regulatory, manufacturing, supply-chain or commercial risks.

What geographic coverage does the patent provide?

US 9,439,921 provides protection only in the United States. Related foreign applications or national-stage patents may exist, but they must be assessed separately by jurisdiction.

The relevant commercial jurisdictions for cangrelor may include:

  • United States
  • European Union member states
  • United Kingdom
  • Canada
  • Japan
  • Australia
  • China

A US patent does not prevent manufacture, sale or use outside the United States. It can, however, affect US importation, commercial launch, packaging, and supply from foreign manufacturing sites when the resulting product enters the US market.

Key Takeaways

  • US 9,439,921 is a formulation and packaging patent for stable cangrelor products.
  • Its core limitations are low moisture, pH of approximately 7.0-9.5, and specified limits for five cangrelor degradants.
  • Claims 14-26 narrow the formulation to cangrelor with mannitol and/or sorbitol.
  • The patent does not broadly claim the cangrelor molecule or all cangrelor uses.
  • The sealed-vessel claims add nitrogen or argon packaging and six- or 12-month stability requirements.
  • Kengreal’s three-year FDA exclusivity ended in 2018, but patent protection is separate and may extend materially later.
  • A generic applicant’s principal strategies are Paragraph IV litigation, excipient substitution, impurity-profile design-around, and delayed launch.
  • Cangrelor is a small molecule, so generic-drug and Hatch-Waxman rules apply rather than biosimilar rules.
  • The patent estate is commercially meaningful but technically narrow compared with a composition-of-matter patent.

FAQs

Does US 9,439,921 claim Kengreal by brand name?

No. The patent claims cangrelor formulations and sealed vessels meeting specified technical limitations. It does not depend on the Kengreal trademark.

Can a generic use cangrelor with an excipient other than mannitol or sorbitol?

Potentially. A different excipient may avoid the narrower claims directed to mannitol and/or sorbitol, but the broader formulation claims must still be analyzed.

Is a cangrelor injectable product automatically covered by this patent?

No. The product must satisfy each limitation of at least one asserted claim, including the moisture, pH and impurity requirements where applicable.

Are impurities A through E ordinary cangrelor impurities?

They are selected hydrolysis and oxidation degradants identified by the patent. Their exact chemical identities and analytical methods must be determined from the patent specification and associated regulatory documentation.

Does patent expiration eliminate all barriers to generic cangrelor entry?

No. Expiration removes the patent barrier for the expired claims, but FDA approval requirements, manufacturing capacity, API supply, quality validation and commercial contracting remain relevant.

References

  1. U.S. Food and Drug Administration. (2015). Kengreal (cangrelor) prescribing information. FDA.

  2. United States Patent and Trademark Office. (2016). U.S. Patent No. 9,439,921: Stable formulations of cangrelor. USPTO.

  3. 35 U.S.C. § 154. Patent term.

  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j). Abbreviated applications and patent certifications.

  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

  6. Public Health Service Act, 42 U.S.C. § 262(k). Biosimilar biological product applications.

  7. The Medicines Company. (2016). Corporate and product-rights disclosures concerning Kengreal. Company filings.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,439,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 AP RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,439,921

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112017014996 ⤷  Start Trial
Canada 2971868 ⤷  Start Trial
Chile 2017001840 ⤷  Start Trial
China 107206014 ⤷  Start Trial
China 115990138 ⤷  Start Trial
Colombia 2017006958 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.